Literature DB >> 16164200

Usefulness of [18F]FDG-PET kinetic analysis in non-enhancing primary central nervous system lymphoma: case report.

Nobuyuki Kawai1, Masahiko Kawanishi, Takashi Tamiya, Seigo Nagao.   

Abstract

A 62-year-old woman experienced headache and rapidly progressive left hemiparesis over 2 weeks. Diffusion-weighted and fluid-attenuated inversion recovery MR images of the head showed increased signal intensity in the right basal ganglia, periventricular white matter and the brain stem. Enhancement was not observed on a T1-weighted spin-echo MR image after the administration of a contrast material. An 18F-fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) study with kinetic analysis showed decreased FDG transport and increased hexokinase activity in the lesions compared with the contralateral hemisphere. The diagnosis was made by biopsy of the right caudate head and pathologic specimens were positive for malignant large-cell lymphoma, B-cell phenotype. The patient received high-dose methotrexate with CHOP chemotherapy, and an [18F]FDG-PET study with kinetic analysis showed decreased hexokinase activity after the first chemotherapy. Kinetic [18F]FDG-PET analysis may be useful to diagnose and monitor the treatment effect in non-enhancing primary central nervous system lymphoma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16164200     DOI: 10.1007/bf03027408

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  2 in total

1.  The clinical heterogeneity of entirely nonenhancing CNS lymphoma: a case series.

Authors:  Stephen G Bowden; Daniel N Munger; Jaclyn Thiessen; S Cody Schoettler Woll; Seunggu J Han; Edward A Neuwelt; Ramon F Barajas; Prakash Ambady
Journal:  CNS Oncol       Date:  2020-12-16

2.  Neuroradiological features of lymphomatosis cerebri: A systematic review of the English literature with a new case report.

Authors:  Long Li; Jia-Hui Rong; Jie Feng
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.